Zepbound®
Injectable
Membership
FDA-Approved Zepbound® (tirzepatide) Injection
Zepbound® is manufactured by Eli Lilly and Company and available through the LillyDirect® pharmacy program to eligible patients following an online medical evaluation, with dosing managed by a licensed provider.
$95 monthly membership
Free shipping directly to your door, with ongoing support from your care team.
No long-term commitment — manage or cancel your membership anytime.
Provider-managed dosing with ongoing support throughout your program.
FDA-approved medication manufactured by Eli Lilly, backed by clinical research.
How It Works
Complete a private online intake, get reviewed by a licensed provider, and receive your personalized Zepbound plan — shipped monthly to your door.
WHAT PEOPLE ARE SAYING“Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes.”
—John Sharretts, M.D., U.S. Food & Drug Administration, on the approval of Zepbound®
Individual results may vary. Testimonials reflect individual experiences and are not a guarantee of results.FREQUENTLY ASKED QUESTIONS
-
Yes. Zepbound® (tirzepatide) is FDA-approved and manufactured by Eli Lilly and Company. It’s prescribed only after an online medical consultation with a licensed provider who determines it’s clinically appropriate for you.
-
After you complete a short online intake, a licensed provider reviews your health history and goals to determine whether Zepbound is clinically appropriate for you.
-
Yes. Your subscription can be canceled at any time — there’s no long-term commitment required.
-
A licensed provider reviews your intake, typically within 1-2 business days. If appropriate, they’ll prescribe your personalized plan, which ships monthly. If it’s not a fit, you’ll be notified and won’t be charged.
-
Some insurance plans offer partial coverage for Zepbound. Your intake and provider consultation costs are outlined before you begin, with transparent, all-inclusive pricing.